Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03266640 · ClinicalTrials.gov registry record · Phase 2

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

A Phase 2 study of Cytomegalovirus Infections and Primary Immune Deficiency Disorder, sponsored by New York Medical College.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
9
Study locations

NCT03266640 is a Phase 2 study of Cytomegalovirus Infections and Primary Immune Deficiency Disorder that is actively recruiting participants, run by New York Medical College. The registered enrollment target is 20 participants, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (90% lower). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03266640, a Phase 2 study of Cytomegalovirus Infections and Primary Immune Deficiency Disorder, is actively recruiting participants, sponsored by New York Medical College.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
9
Study locations

Study Summary

CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

Conditions Studied

Cytomegalovirus Infections Primary Immune Deficiency Disorder

Interventions

  • DRUG viral specific cytotoxic t-lymphocytes

Study Locations (9)

California

  • Children's Hospital Los Angeles - Los Angeles
  • University of California San Francisco - San Francisco

Indiana

  • Indiana University - Indianapolis

Maryland

  • Johns Hopkins - Baltimore

Missouri

  • Washington University - St Louis

New York

  • New York Medical College - Valhalla

Ohio

  • Nationwide Children's Hosptial - Columbus

Pennsylvania

  • Children's Hospital of Pennsylvania - Philadelphia

Wisconsin

  • Medical College of Wisconsin/Children's Hospital of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2018-11-01
Est. Completion 2027-12-31
Phase Phase 2

Sponsor

New York Medical College

47 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03266640

The ClinicalTrials.gov registry entry for NCT03266640 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (90% lower). The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which viral specific cytotoxic t-lymphocytes is the first listed.

NCT03266640 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Indiana, Maryland.

Frequently Asked Questions

What is clinical trial NCT03266640 about?

NCT03266640 is a clinical study titled "Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)". CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary...

What is the current status of trial NCT03266640?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-11-01. Estimated completion is 2027-12-31.

What conditions does trial NCT03266640 study?

This clinical trial studies the following conditions: Cytomegalovirus Infections, Primary Immune Deficiency Disorder.

What interventions are being tested in trial NCT03266640?

The interventions under investigation include: viral specific cytotoxic t-lymphocytes (DRUG).

Who is sponsoring clinical trial NCT03266640?

This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03266640 being conducted?

This trial has 9 study locations across California, Indiana, Maryland, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cytomegalovirus Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cytomegalovirus Infections

All registered trials for this condition

Primary Immune Deficiency Disorder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.